News Snapshot:
All news Russian Direct Investment Fund agrees production of 100 mln doses of Sputnik V in China Russian Direct Investment Fund (RDIF) and TopRidge Pharma have agreed production of over 100 mln doses of the anti-coronavirus vaccine Sputnik V per year in China, the Fund said in a statement on Thursday. Read also Austria’s talks with Russia on purchase of Sputnik V move into final stretch "The Russian Direct Investment Fund and TopRidge Pharma (a subsidiary company of one of China’s pharmaceutical market leaders, Tibet Rhodiola Pharmaceutical Holding) have agreed to cooperate on production of over 100 million doses per...
